Analysts at UOB Kay Hian remain positive on Hansoh Pharmaceutical Group, keeping a Buy rating despite lowering the target price due to recent market sentiment weakness.
Key Highlights from the Report
1) Innovative Drugs Driving Growth
Hansoh’s 2025 performance was strong, mainly due to:
- Rapid growth in innovative drug sales
- Increased collaboration revenue (partnership deals with other pharma firms)
- Expansion beyond traditional generic drugs into higher-margin therapies
Management expects innovative medicines to remain the core growth engine, supporting double-digit revenue growth in 2026.
Why this matters:
Innovative drugs typically have higher margins and longer product life, making earnings more sustainable compared with generic medicines.
2) Double-Digit Growth Expected in 2026
The company’s outlook includes:
- Double-digit expansion in drug sales
- Continued growth in business development income
- Strong pipeline momentum supporting long-term profitability
This indicates that Hansoh is transitioning into a research-driven pharmaceutical model, which usually commands higher valuations in the market.
3) Target Price Cut — But Rating Still Buy
The brokerage reduced its target price:
- New target: HK$45.00
- Previous target: HK$50.00
- Latest share price: HK$39.36
The reduction was not due to company weakness, but mainly:
- Weak overall market sentiment
- External pressures affecting Chinese healthcare stocks
This implies the downgrade is macro-driven, not fundamental-driven.
What Investors Should Watch
Bullish Factors
- Strong innovative drug pipeline
- Growing collaboration partnerships
- Expected double-digit growth in 2026
- Share price still below target level (potential upside)
Risks
- Market sentiment toward Chinese equities
- Regulatory changes in China’s healthcare sector
- Competition from other innovative drug makers
Strategic Interpretation
Short-Term:
Stock movement may remain volatile due to broader market sentiment.
Medium-Term:
Innovative product launches could continue boosting revenue and margins.
Long-Term:
If pipeline execution remains strong, Hansoh could evolve into a high-growth biotech-style pharmaceutical company.
Bottom Line
Hansoh Pharmaceutical Group remains fundamentally strong, with innovative drug launches expected to support double-digit growth in 2026. Although the target price was lowered to HK$45 due to weak market sentiment, analysts still see meaningful upside from the current price of HK$39.36, reinforcing a positive long-term outlook.